Collegium Pharmaceutical (COLL) Gross Margin (2016 - 2026)

Collegium Pharmaceutical has reported Gross Margin for 11 years, with the latest figure at 55.18% in Q2 2026.

• On a quarterly basis, Gross Margin fell 247.0% year-over-year to 55.18% in Q2 2026; TTM through Jun 2026 was 60.02%, a 333.0% increase from a year earlier, with the FY2025 full-year figure at 59.35%, down 41.0% from the prior year.
• Gross Margin was 55.18% for Q2 2026 at Collegium Pharmaceutical, down from 60.59% in the prior quarter.
• The five-year high for Gross Margin was 63.19% in Q4 2023, with the low at 35.4% in Q4 2022.
• Average Gross Margin over 5 years is 55.81%, with a median of 57.78% recorded in 2022.
• The largest YoY upside for Gross Margin was 4027 bps in 2022 against a maximum downside of 1819 bps in 2022.
• Over 5 years, Gross Margin stood at 35.4% in 2022, then soared by 79 bps to 63.19% in 2023, then slipped by 15 bps to 54.02% in 2024, then advanced by 16 bps to 62.49% in 2025, then decreased by 12 bps to 55.18% in 2026.
• The last three Gross Margin figures came in at 55.18% (Q2 2026), 60.59% (Q1 2026), and 62.49% (Q4 2025), per Business Quant data.